PHT1 Antibody

What is PHT1 and why are antibodies against it important in research?

PHT1 (also known as solute carrier family 15 member 4) is a 577-amino acid residue protein encoded by the SLC15A4 gene in humans. It functions as a histidine/oligopeptide transporter and plays essential roles in innate immune responses, particularly through Toll-like receptor signaling pathways . PHT1 is primarily localized to the lysosomes of cells and is highly expressed in skeletal muscle tissue . The protein belongs to the proton-coupled oligopeptide transporter (POT) family, which includes five members with distinct expression profiles and biological functions .

Antibodies against PHT1 are crucial research tools for several reasons. First, they enable detection and quantification of PHT1 protein in various experimental systems, helping researchers understand its expression patterns and regulation. Second, they facilitate the study of PHT1's role in immune signaling, particularly its interaction with TASL (TRIF-related adaptor molecule associated with SLC15A4-dependent signaling), which leads to type I interferon production via IRF5 . This pathway has significant implications for autoimmune diseases like systemic lupus erythematosus (SLE). Third, PHT1 antibodies allow researchers to investigate the protein's subcellular localization and potential conformational changes during transport cycles.

Recent structural studies have determined the Cryo-EM structure of PHT1 stabilized in the outward-open conformation, providing critical insights into its molecular function . This structural knowledge enhances the value of PHT1 antibodies as tools for studying structure-function relationships in this important immune regulator.

What is the relationship between PHT1, SLC15A4, and the innate immune system?

SLC15A4 is the gene that encodes the PHT1 protein, with PHT1 serving as an alias for the protein product . The innate immune system utilizes PHT1/SLC15A4 in several crucial ways that extend beyond its traditional role as a transporter. PHT1 acts as a receptor by recruiting the adaptor protein TASL, which activates IRF5 and leads to type I interferon production . This signaling cascade is a critical component of innate immune responses, particularly those involved in antiviral defense.

In dendritic cells and B cells, PHT1's transport function helps maintain proper pH and ion balance in lysosomes, which is essential for antigen processing and presentation. Additionally, PHT1's role in peptide transport may influence the peptide repertoire available for presentation to immune cells. The protein's unique lysosomal localization distinguishes it from other POT family members, which are primarily found at the plasma membrane .

Persistent stimulation of the PHT1-TASL-IRF5 signaling pathway has been implicated in the pathogenesis of systemic lupus erythematosus, highlighting the protein's importance in maintaining immune homeostasis . Understanding this relationship provides essential context for researchers designing experiments with PHT1 antibodies in immunological studies.

What are the typical applications of PHT1 antibodies in immunological research?

PHT1 antibodies serve as versatile tools in immunological research, with applications spanning multiple techniques:

Western Blotting: The most common application, allowing researchers to detect and quantify PHT1 protein levels in cell and tissue lysates . This technique is particularly valuable for studying PHT1 expression under different conditions or in various disease models.

Immunoprecipitation: Used to isolate PHT1 and its interacting partners, such as TASL, enabling the study of protein complexes involved in immune signaling .

Immunofluorescence/Immunohistochemistry: Allows visualization of PHT1's subcellular localization, confirming its presence in lysosomes and potentially identifying other cellular compartments where it may function.

Flow Cytometry: Enables analysis of PHT1 expression in specific immune cell populations, helping researchers understand cell type-specific roles of the protein.

Proximity Ligation Assays: Valuable for studying in situ protein-protein interactions between PHT1 and binding partners like TASL in the context of immune signaling .

Structural Studies: PHT1 antibodies can be used to validate protein purification and conformational states in preparation for techniques like Cryo-EM that have revealed critical insights into PHT1 structure .

Each application requires antibodies with specific characteristics, and researchers should select PHT1 antibodies validated for their particular experimental approach from among the 92 commercially available options across multiple suppliers .

How does PHT1 function differ from other members of the POT family?

The Proton-coupled Oligopeptide Transporter (POT) family in humans includes five members with distinct features and functions:

PHT1 has several unique characteristics that distinguish it from other family members :

Subcellular Localization: Unlike PepT1 and PepT2, which are primarily localized to the plasma membrane, PHT1 is predominantly found in lysosomal membranes, suggesting a role in intracellular peptide transport rather than cellular uptake.

Signaling Function: PHT1 has a dual role as both a transporter and a signaling molecule through its interaction with TASL, which is not a described function for other POT family members .

Immune Relevance: PHT1 plays a critical role in innate immune signaling, particularly in the production of type I interferons, a function not shared by other POT transporters.

Disease Associations: PHT1 has been specifically linked to autoimmune diseases like SLE, whereas other POT family members have different clinical associations, such as PepT1's role in drug absorption .

Understanding these differences is essential for researchers working with PHT1 antibodies to properly interpret their findings in the context of specific transporter biology.

What is the tissue expression profile of PHT1 in humans?

PHT1 (SLC15A4) shows a distinct tissue expression pattern in humans that informs its biological functions:

Skeletal Muscle: PHT1 is highly expressed in skeletal muscle tissue, suggesting important roles in muscle metabolism or peptide transport in this tissue .

Immune Cells: Significant expression is found in various immune cell types, particularly dendritic cells, B cells, and certain T cell subsets, aligning with its role in innate immune signaling .

Lymphoid Tissues: PHT1 is expressed in the spleen, lymph nodes, and bone marrow, further supporting its importance in immune function.

When using PHT1 antibodies for tissue studies, researchers should consider this expression profile both as a guide for expected signal intensity and as a reference for biological interpretation of results. Positive and negative control tissues should be selected based on this known expression pattern, with skeletal muscle serving as an excellent positive control .

How can PHT1 antibodies be used to study the PHT1-TASL interaction in autoimmune disease models?

The PHT1-TASL interaction represents a critical junction in the signaling pathway leading to type I interferon production, which is often dysregulated in autoimmune diseases like SLE . Researchers can employ several sophisticated approaches using PHT1 antibodies to investigate this interaction:

Co-immunoprecipitation with Site-Specific Mutants: Using PHT1 antibodies to pull down wild-type and mutant PHT1 proteins can help identify specific residues critical for TASL binding. This approach, combined with the recent Cryo-EM structural data of PHT1, allows for structure-function analyses of the interaction interface .

Proximity Ligation Assays (PLA): This technique can visualize and quantify the PHT1-TASL interaction in situ within cells derived from autoimmune disease models or patient samples. PHT1 antibodies are paired with TASL antibodies to generate fluorescent signals only when the proteins are in close proximity (<40nm).

Competitive Binding Assays: PHT1 antibodies targeting specific epitopes can be used to disrupt the PHT1-TASL interaction, helping map the interaction interface and potentially identifying therapeutic intervention points.

Patient-Derived Sample Analysis: PHT1 antibodies can be used to compare PHT1-TASL interaction levels in samples from autoimmune disease patients versus healthy controls, potentially identifying correlations with disease severity or treatment response.

The current molecular model suggests that the first 16 N-terminal TASL residues fold into a helical structure that binds in the central cavity of the inward-open conformation of PHT1 . This structural knowledge can guide the selection of appropriate PHT1 antibodies that don't interfere with this interaction site when the goal is to preserve and study the native interaction.

What are the best methods for validating PHT1 antibody specificity and sensitivity?

Rigorous validation of PHT1 antibodies is essential for generating reliable research data. The following complementary approaches should be employed:

Knockout/Knockdown Controls: The gold standard for antibody validation is testing in cells with PHT1/SLC15A4 gene knockout (CRISPR-Cas9) or knockdown (siRNA/shRNA). A specific antibody should show significantly reduced or absent signal in these samples.

Overexpression Systems: Complementary to knockout approaches, testing the antibody in cells overexpressing tagged PHT1 can confirm detection of the target protein.

Peptide Competition Assays: Pre-incubation of the antibody with the immunizing peptide should block specific binding. This approach is particularly valuable for polyclonal antibodies.

Multiple Antibody Comparison: Using different antibodies targeting distinct epitopes of PHT1 should yield consistent results in the same experimental system. The availability of 92 PHT1 antibodies across 6 suppliers provides ample options for this approach .

Cross-Reactivity Testing: Evaluating antibody reactivity against other POT family members (PepT1, PepT2, PHT2) can confirm specificity within this related protein group.

Mass Spectrometry Validation: Immunoprecipitation followed by mass spectrometry analysis can confirm that the antibody is pulling down PHT1 and identify potential cross-reactive proteins.

Tissue Panel Testing: The antibody should detect PHT1 in a pattern consistent with known tissue expression profiles, with strong signals in skeletal muscle and immune tissues .

Appropriate validation strategy selection depends on the intended application (Western blot, IHC, flow cytometry, etc.) as antibodies may perform differently across methods.

How can researchers effectively use PHT1 antibodies to investigate lysosomal membrane protein complexes?

Investigating lysosomal membrane protein complexes involving PHT1 requires specialized approaches due to the challenges of working with membrane proteins in an acidic organelle environment:

Subcellular Fractionation: Begin with optimized protocols for lysosomal isolation, using differential centrifugation combined with density gradient separation. PHT1 antibodies can be used to track purification efficiency by Western blotting fractions alongside lysosomal markers (LAMP1, LAMP2).

Mild Detergent Solubilization: Lysosomal membrane proteins should be solubilized using detergents that preserve protein-protein interactions (e.g., digitonin, CHAPS, or Brij-35) rather than harsh detergents like SDS. The efficiency of PHT1 extraction can be monitored using the antibodies.

Blue Native PAGE: This technique separates intact protein complexes while maintaining native protein interactions. PHT1 antibodies can be used for Western blotting after BN-PAGE to identify complexes containing PHT1.

Co-immunoprecipitation with Crosslinking: Prior to lysis, membrane proteins can be crosslinked to stabilize transient interactions. PHT1 antibodies can then immunoprecipitate these complexes for subsequent analysis.

Super-Resolution Microscopy: Techniques like STORM or PALM using fluorophore-conjugated PHT1 antibodies can visualize nanoscale organization of PHT1 within lysosomal membranes, particularly in relation to its interaction partner TASL .

Mass Spectrometry Analysis: After immunoprecipitation with PHT1 antibodies, complexes can be analyzed by mass spectrometry to identify novel interaction partners beyond the known TASL adaptor protein .

A multi-method approach is recommended, as each technique has strengths and limitations when applied to lysosomal membrane protein complexes, particularly given PHT1's multiple conformational states identified through Cryo-EM studies .

What are the key considerations for using PHT1 antibodies to study the role of PHT1 in type I interferon production?

When investigating the critical role of PHT1 in type I interferon production, researchers should consider several important factors:

Conformational Specificity: PHT1, like other MFS transporters, exists in multiple conformational states (outward-open, occluded, inward-open) . Antibodies may preferentially recognize specific conformations, which can affect their utility in studying the conformation-dependent interaction with TASL. Consider using multiple antibodies targeting different epitopes.

Stimulation Conditions: Type I interferon production via PHT1-TASL is typically triggered by specific stimuli, such as TLR7/9 agonists. When designing experiments, carefully time the stimulation and sample collection to capture the dynamic range of the response.

Cell Type Selection: PHT1's role in interferon production varies across cell types. Plasmacytoid dendritic cells and B cells show strong PHT1-dependent interferon responses, while other cell types may utilize alternative pathways. Choose appropriate cellular models for your research question.

Signaling Complex Assembly: The PHT1-TASL-IRF5 signaling axis involves dynamic complex formation . Consider using proximity ligation assays with antibodies against PHT1 and TASL or IRF5 to monitor complex assembly kinetics after stimulation.

Transport vs. Signaling Functions: Design experiments that can distinguish between PHT1's transport activity and its signaling function, potentially using transport-deficient mutants while preserving TASL binding capacity .

Understanding the molecular basis of the PHT1-TASL recruitment, as revealed by recent structural studies, provides a framework for experimental design. The proposed model of the PHT1-TASL complex involves the N-terminal TASL residues folding into a helical structure that binds in the central cavity of the inward-open conformation of PHT1 .

How do researchers address epitope accessibility challenges when targeting PHT1 with antibodies?

PHT1, as a multi-pass membrane protein primarily localized to lysosomal membranes, presents significant epitope accessibility challenges that researchers must overcome:

Epitope Selection Strategies:

• Target extramembrane domains: Focus on antibodies recognizing the N-terminal, C-terminal, or larger loop regions between transmembrane segments.

• Consider conformation-specific epitopes: Some applications may benefit from antibodies that recognize specific conformational states of PHT1, particularly when studying the interaction with TASL which depends on the inward-open conformation .

• Avoid highly conserved regions if specificity among POT family members is desired.

Application-Specific Optimization:

For Western Blotting:

• Optimize denaturation conditions, potentially using multiple detergents (SDS, NP-40, Triton X-100) to adequately expose epitopes.

• Consider membrane protein extraction protocols specifically designed for lysosomal proteins.

• Test both reducing and non-reducing conditions, as disulfide bonds may affect epitope accessibility.

For Immunoprecipitation:

• Use mild detergents (digitonin, CHAPS) that solubilize membranes while preserving native protein conformation.

• Consider crosslinking approaches to stabilize protein complexes before extraction, particularly when studying the PHT1-TASL interaction .

For Immunofluorescence/IHC:

• Test multiple fixation protocols, as paraformaldehyde may preserve structure but limit accessibility to some epitopes.

• Optimize permeabilization conditions using detergents of varying strengths (saponin for gentle permeabilization of intracellular membranes, Triton X-100 for stronger permeabilization).

• Consider antigen retrieval methods (heat-induced, enzymatic) to expose masked epitopes in fixed tissues.

By systematically addressing these accessibility challenges, researchers can significantly improve the reliability and sensitivity of experiments targeting PHT1 with antibodies, particularly in the context of studying its role in autoimmune disease pathogenesis .

What are the optimal fixation and permeabilization methods for PHT1 immunostaining in different cell types?

Optimizing fixation and permeabilization for PHT1 immunostaining requires careful consideration of its lysosomal localization and membrane topology. Different cell types require distinct protocols:

Immune Cells (Dendritic Cells, B Cells):

• Fixation: 4% paraformaldehyde for 10-15 minutes at room temperature preserves cellular architecture while allowing some epitope accessibility.

• Permeabilization: Staged approach - first with 0.1% saponin (15 minutes) to gently permeabilize membranes, particularly lysosomal membranes, followed by brief treatment with 0.1% Triton X-100 (5 minutes) if needed for deeper epitope access.

• Buffer system: PBS with 0.1% saponin maintained throughout the staining process helps preserve permeabilization.

Skeletal Muscle Cells:

• Fixation: 2% paraformaldehyde with 0.2% glutaraldehyde better preserves the dense cytoskeletal structure while maintaining PHT1 antigenicity.

• Permeabilization: 0.2-0.5% Triton X-100 for 15-20 minutes, as muscle cells require stronger permeabilization.

• Consider mechanical disruption (freeze-thaw cycles) before antibody incubation to enhance accessibility in these high-expression tissues .

General Recommendations:

• Always include positive control cells with known high PHT1 expression (e.g., skeletal muscle cells) .

• Test multiple PHT1 antibodies recognizing different epitopes as accessibility may vary.

• For co-localization studies with lysosomal markers, ensure compatible fixation/permeabilization for all target proteins.

• When comparing PHT1 expression across conditions, maintain identical fixation/permeabilization parameters.

When studying the PHT1-TASL interaction, which is critical for understanding autoimmune disease mechanisms , additional care must be taken to preserve this interaction during fixation and permeabilization steps, potentially using milder conditions or specific crosslinking approaches.

How can PHT1 antibodies be effectively used in co-immunoprecipitation studies to identify novel interaction partners?

Co-immunoprecipitation (Co-IP) using PHT1 antibodies presents unique challenges due to PHT1's membrane localization and potential transient interactions. The following comprehensive approach can maximize success:

Sample Preparation:

• Cell choice: Select cells with endogenous PHT1 expression (e.g., B cells) or stable transfectants for consistent results.

• Stimulation: Consider comparing resting vs. activated states (e.g., TLR7/9 ligands) to capture stimulus-dependent interactions.

• Crosslinking: For transient interactions, use membrane-permeable crosslinkers like DSP (dithiobis[succinimidyl propionate]) or formaldehyde (0.5-1%, 10 minutes).

Membrane Protein Solubilization:

• Detergent selection: Test a panel of non-ionic and zwitterionic detergents (digitonin 1%, CHAPS 1%, Brij-35 0.5%) that solubilize membranes while preserving protein-protein interactions.

• Lysis buffer optimization: Include protease inhibitors, phosphatase inhibitors, and appropriate salt concentration (150-300 mM NaCl) to maintain ionic interactions.

• Solubilization time: Gentle rotation for 1-2 hours at 4°C rather than brief vigorous lysis.

Immunoprecipitation Strategy:

• Antibody selection: Use antibodies validated for IP applications, choosing from among the 92 commercially available options .

• Pre-clearing: Extensively pre-clear lysates with protein A/G beads to reduce non-specific binding.

• IP controls: Include isotype control antibodies and PHT1-knockout/knockdown samples as negative controls.

• Sequential IP: For identification of multi-protein complexes, consider sequential IPs using antibodies against PHT1 followed by known interactors (e.g., TASL).

Interaction Verification Approaches:

• Reciprocal Co-IP: Confirm interactions by IP with antibodies against the potential partner followed by PHT1 Western blotting.

• Competitive peptide approach: Use peptides corresponding to predicted interaction domains to disrupt specific interactions.

• Mutation analysis: Introduce specific mutations in PHT1 to map interaction domains, informed by recent structural data .

This methodical approach can reveal novel PHT1 interaction partners involved in transport, immune signaling, or trafficking functions, potentially identifying new therapeutic targets for autoimmune diseases like SLE .

What are the advantages and limitations of different PHT1 antibody types (monoclonal vs. polyclonal) for specific applications?

Different types of PHT1 antibodies offer distinct advantages and limitations that should guide selection for specific applications:

Monoclonal Antibodies:

Advantages:

• High specificity for a single epitope, reducing cross-reactivity with related POT family members

• Consistent lot-to-lot reproducibility, enabling reliable long-term studies

• Excellent for applications requiring high specificity such as ChIP, flow cytometry, and therapeutic development

• Often superior for detecting specific conformational states of PHT1, which is relevant given its multiple structural conformations identified by Cryo-EM

Limitations:

Polyclonal Antibodies:

Advantages:

Limitations:

• Batch-to-batch variability requiring revalidation with new lots

• Higher potential for cross-reactivity with related proteins

• Less suited for discriminating specific protein conformations

Application-Specific Recommendations:

What controls should be included when using PHT1 antibodies in studies of autoimmune diseases?

Rigorous control implementation is essential when using PHT1 antibodies to study autoimmune diseases, ensuring that findings accurately reflect PHT1 biology rather than technical artifacts:

Antibody Validation Controls:

• Genetic knockout/knockdown: Include SLC15A4-knockout cells/tissues as negative controls to confirm antibody specificity.

• Peptide competition: Pre-incubate PHT1 antibody with immunizing peptide to demonstrate binding specificity.

• Isotype controls: Include matched isotype antibodies to distinguish specific from non-specific binding.

• Multiple antibody validation: Use different PHT1 antibodies targeting distinct epitopes to confirm consistent results, choosing from the 92 commercially available options .

Biological Sample Controls:

• Healthy vs. disease samples: Include age/sex-matched healthy controls alongside autoimmune disease samples.

• Disease spectrum representation: Include samples from multiple disease stages/severities to capture disease dynamics.

• Treatment-naive vs. treated samples: Compare patients before and after therapeutic intervention to assess treatment effects on PHT1.

• Related autoimmune conditions: Include samples from distinct autoimmune diseases to identify PHT1 alterations specific to certain conditions.

Experimental Design Controls:

• Cell activation state controls: Compare resting vs. stimulated cells to distinguish baseline from induced changes.

• Pharmacological modulation: Use inhibitors of signaling pathways to establish mechanistic relationships.

• Time course analysis: Include multiple time points to capture dynamic changes in PHT1 expression or localization.

Signaling Pathway Controls:

• Upstream regulator manipulation: Modulate TLR7/9 to confirm pathway-specific effects.

• Downstream effector assessment: Monitor IRF5 phosphorylation and nuclear translocation as functional readouts .

• Parallel pathway analysis: Examine alternative interferon-production pathways to distinguish PHT1-specific effects.

These comprehensive controls enable confident interpretation of PHT1 antibody data in the complex context of autoimmune disease research, particularly when investigating the PHT1-TASL-IRF5 signaling axis implicated in SLE pathogenesis .

How can researchers troubleshoot non-specific binding issues with PHT1 antibodies?

Non-specific binding is a common challenge when working with antibodies against membrane proteins like PHT1. A systematic troubleshooting approach includes:

Identifying the Problem:

• Characterize the pattern: Multiple unexpected bands in Western blot, diffuse staining in immunofluorescence, or high background signal may indicate non-specific binding.

• Compare with known PHT1 expression patterns: Signal in tissues/cells known to lack PHT1 suggests non-specificity.

• Evaluate negative controls: Strong signals in SLC15A4 knockout samples confirm non-specific binding issues.

Western Blot Optimization:

• Blocking optimization: Test different blocking agents (5% milk, 5% BSA, commercial blockers) and extended blocking times (2-3 hours).

• Antibody dilution series: Prepare a dilution series (1:500 to 1:5000) to identify optimal concentration balancing specific signal and background.

• Stringent washing: Increase wash duration and buffer stringency (add 0.1-0.5% SDS or increase NaCl to 500mM in wash buffers).

• Alternative membrane types: Compare PVDF (higher protein binding) vs. nitrocellulose (lower background) membranes.

Immunofluorescence/IHC Troubleshooting:

• Autofluorescence control: Image unstained samples to identify intrinsic tissue fluorescence.

• Antibody titration: Determine optimal antibody concentration through systematic dilution series.

• Preincubation: Preincubate diluted antibody with 1-5% serum from the same species as the sample.

• Alternative fixation: Compare paraformaldehyde, methanol, and acetone fixation effects on background.

• Secondary antibody controls: Include samples with only secondary antibody to identify non-specific secondary binding.

Immunoprecipitation Optimization:

• Pre-clearing: Extensively pre-clear lysates with protein A/G beads before adding the PHT1 antibody.

• Detergent optimization: Test different detergent types and concentrations to reduce non-specific membrane protein interactions.

• Salt concentration: Increase NaCl concentration (300-500mM) in wash buffers to disrupt low-affinity interactions.

General Solutions:

• Antibody purification: Consider affinity purification of polyclonal antibodies against the specific antigen.

• Cross-adsorption: Remove cross-reactive antibodies by pre-incubation with related proteins or tissues lacking PHT1.

• Alternative detection systems: Switch between chemiluminescence, fluorescence, and colorimetric detection to identify optimal signal-to-noise ratio.

• Epitope-targeted approach: If certain regions of PHT1 lead to cross-reactivity, select antibodies targeting unique regions.

Systematic documentation of each troubleshooting step helps identify optimal conditions for specific research applications, particularly when studying PHT1's role in autoimmune disease mechanisms .